Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Mimedx (MDXG) over the last 10 years, with Q3 2025 value amounting to $2.1 million.

  • Mimedx's Asset Writedowns and Impairment rose 83691.76% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 32288.73%. This contributed to the annual value of $595000.0 for FY2024, which is 5893.72% down from last year.
  • Latest data reveals that Mimedx reported Asset Writedowns and Impairment of $2.1 million as of Q3 2025, which was up 83691.76% from $351000.0 recorded in Q2 2025.
  • Mimedx's 5-year Asset Writedowns and Impairment high stood at $2.2 million for Q2 2022, and its period low was -$279000.0 during Q3 2024.
  • For the 5-year period, Mimedx's Asset Writedowns and Impairment averaged around $525866.7, with its median value being $351000.0 (2025).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first surged by 2363333.33% in 2023, then crashed by 16241.61% in 2024.
  • Mimedx's Asset Writedowns and Impairment (Quarter) stood at $100000.0 in 2021, then plummeted by 97.0% to $3000.0 in 2022, then surged by 23633.33% to $712000.0 in 2023, then tumbled by 36.24% to $454000.0 in 2024, then surged by 352.86% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $351000.0 for Q2 2025, and $742000.0 during Q1 2025.